Do I Continue or Stop Medications During Pregnancy and ......prospective study of adalimumab in...
Transcript of Do I Continue or Stop Medications During Pregnancy and ......prospective study of adalimumab in...
1
Uma Mahadevan-Velayos MD
Associate Professor of Medicine
UCSF Center for Colitis and Crohn’s Disease
San Francisco, CA
Do I Continue or Stop
Medications During Pregnancy
and Lactation?
1
2
Prior to Pregnancy
• Discuss risks and benefits of medications
prior to pregnancy
• There is a risk to stopping medication
– A disease flare may be more harmful to the
pregnancy than the medication
• Involve the obstetrician and pediatrician for
a multidisciplinary approach
3
FDA Pregnancy Category
Category Description
A Controlled studies show no risk
B No evidence of risk in humans
C • Animal reproduction studies show adverse effects
• No adequate studies in humans
• Benefits in pregnant women may be acceptable despite
potential risk
D Positive evidence of risk
X Contraindicated in pregnancy
4
Fish Oil
• Essential Fatty acids (EFA) and
Docosahexaenoic acid (DHA)
– Potential antithrombotic effect
– Prolong gestation
– No evidence of prevention of proteinuric
pregnancy
• Benefit in Crohn’s disease?
5
Aminosalicylates (B,C)
• Meta-analysis of 7 studies of 5-ASAs in pregnant
patients with IBD
– 5-ASA (n=642)
– No medication (n=1158)
Odds Ratio 95% CI
Congenital abnormalities 1.16 0.76-1.77
Stillbirth 2.38 0.65-8.72
Spontaneous abortion 1.14 0.65-2.01
Preterm delivery 1.35 0.85-2.13
Low birth weight 0.93 0.46-1.85
Rahimi R et al. Reprod Toxicol. 2008;25:271-275.
6
Aminosalicylates (B,C)
• Sulfasalazine given w/ folic acid 1 mg BID
– Folic acid: neural tube defects, CV, GU,
cleft palate
– Case reports of congenital malformation
• Placental and breast transfer occurs
– Potential allergic reaction newborn:
watery diarrhea
– SAS not associated with kernicterus or
displacement of bilirubin from albumin
• Olsalazine & Asacol: Pregnancy category C
– All other 5-ASAs, pregnancy category B
Rahimi R et al. Reprod Toxicol. 2008;25:271-275.
7
Corticosteroids (C)
• Case-control study in 1st T– Increased risk of oral clefts
– Overall risk of malformations low
– In transplant setting:• Adrenal suppression in newborn
• Premature rupture of membranes
• Compatible with breast feeding
• Budesonide (Entocort)– Orally inhaled budesonide not associated with
increase risk of fetal abnormalities
– 8 CD patients treated with oral budesonide 1
1. Beaulieu Inflamm Bowel Dis. 2009 Jan;15(1):25-8
8
Antibiotics
• Metronidazole (B) /Ciprofloxacin (C)
– Low risk of teratogenicity
• Metronidazole: prospective controlled study, 2 meta-analysis
– However, 2nd, 3rd T use, 1st T cleft lip, palate
• Ciprofloxacin: prospective controlled study low risk of defects
– Affinity for bones, arthropathy in children
– Breast feeding not advised on MNZL, probably compatible with ciprofloxacin
– Minimal benefit in CD and UC with longer use-avoid
• Rifaximin: Pregnancy C
– Teratogenicity in animal studies
– Safety in humans in pregnancy/breastfeeding unknown
• Augmentin: Pregnancy B
9
6MP/AZA (D)
• Teratogenic in animals (mice, rabbits, rats)– Given IV/IP at supratherapeutic doses. (low oral
bioavailability: 47% AZA, 16% 6MP)
– Increased cleft palate, ocular, skeletal,urogenital anomalies, hydrocephalus
– Poor oral bioavailability may produce levels too low to have substantial teratogenic effect
• Fetal liver in early pregnancy lacks inosinate pyrophosphorylase to convert AZA to active metabolites
Polifka and Friedman (Teratology 65:240-261. 2002)
10
Azathioprine and Teratogenicity
• 189 pregnant women on AZA who contacted 1 of 7 teratogen
information services compared to 230 pregnant women who
took non-teratogenic treatments
AZA No AZA P
Rate of major
malformations
3.5% 3.0% .775
(OR 1.17;
95% CI 0.37-3.69)
Birth weight 2995 3252 .001
Gestational age 37.8 39.1 .001
Premature birth 21.4% 5.2% .001
Low birth weight 23% 6.0% .001
Goldstein Birth Defects Res A Clin Mol Teratol. 2007 Sep 10;79(10):696-701
11
Azathioprine/6MP
• Swedish Medical Birth Register
– 476 women used AZA in early pregnancy
– Most common indication was IBD (>300)
– Rate of CA 6.2% AZA vs. 4.7% other• OR 1.41, 95% CI: 0.98-2.04
– Increased rate of VSD/ASD • OR 3.18, 95% CI: 1.45-6.04
– Increased rate of preterm, LBW, SGA• Likely disease effect
Cleary. Birth Defects Research 85:647-654, 2009
12
Breastfeeding on AZA/6MP
• 8 lactating women received Aza 75-200 QD– Milk and plasma at 30, 60 min and every
hour x 5
• Variation in bioavailability reflected in wide range in milk an plasma first 3 hours
• Major excretion in breast milk within 4 hours of drug intake
• Worst case scenario: max concentration 0.0075 mg/kg– In most cases, will be <10% of maximum
concentration
Christensen APT 2008:28, 1209-1213
13
Avoid Use
Drug Pregnancy
Category
Notes
Diphenoxylate C Teratogenic in animals
Loperamide B Increase in CV defects in 1 study
Bisphosphonates C • Animal studies: Alendronate
crosses placenta
• 24 pregnancies, no increased
teratogenic risk1
Methotrexate X • Known abortifacent
• Teratogenic (skeletal defects; cleft
palate)
Thalidomide X • Birth defects
1. Ornoy. Reproductive Toxicology 22 (2006:578)
14Adapted from: Hanauer SB. Rev Gastroenterol Disord. 2004;4(Suppl. 3):S18-S24.
Monoclonal
antibody
Infliximab Adalimumab
IgG
1Fc
Fab
HumanChimeric
Fab′
Certolizumab
pegol
PEG
PEGylated
humanized
Fab′ fragment
2 × 20 kDa
PEG
Biologics
15
Transfer Across Placenta
• Fetal immunity is acquired by transfer of Ab as IgG from maternal to fetal circulation
• IgG is actively transported across the placenta– Smooth linear rise in fetal IgG as early as 13
weeks (earliest examined), after 32 weeks, significant increase in ratio
• Preferential transport– IgG1>IgG4>IgG3>IgG2
• Certolizumab is a Fab’ fragment – Likely passive diffusion
Kane AJG Jan 2009;104:228-233
16
Placental Transfer of IgG Ab
• INF and ADA are IgG1 antibodies
• Fc portion of IgG actively transported across placenta by specific neonatal FcR
• Highly efficient transfer in 3rd T leads to elevated levels of drug in newborn
Wiley-Blackwell Publishing Ltd. Malek A, Evolution of maternofetal transport of immunoglobulins
During human pregnancy. Am J Reprod Immunol 1996; 36(5):248-55.
Image Courtesy of Sundana Kane MD
r2=0.87, p<0.04
B: Fetal
17
Infliximab (B) Safety Database
0
Pro
po
rtio
n o
f P
ati
en
ts (
%)
General
population
Crohn’s
disease
All infliximab
patients
(N=96)
Infliximab
patients with
CD (N=82)
10
20
30
40
50
60
70
80
67 66 67 67
17 16 17
1115
19 20
13
Live births
Therapeutic
termination
Miscarriages
Outcomes of Women Exposed to
Infliximab During Pregnancy
Katz JA, et al. Am J Gastroenterol. 2004;99:2385-2392.
Ventura et al. National Center for Health Statistics Vital Health Stat 2000;21:1-59
Hudson et al. Int J Gynaecol Obstet 1997;58:229-237.
18
Adalimumab (B)
• OTIS (Organization for Teratology Information Specialists) reports 27 women enrolled in a prospective study of adalimumab in pregnancy and an additional 47 adalimumab exposed pregnant women in a registry– The rate of spontaneous abortion and stillbirth was
similar to the diseased comparison and the general population. The rates of congenital malformation and preterm delivery are also within the expected range
Chambers CD The OTIS Autoimmune Diseases in Pregnancy Project. Personal communication. July 13, 2007 .
19
Biologics and Pregnancy (cont)
• Certolizumab (C): data on file
– 16 pregnancies:
• 4 healthy infants, 8 IAB, 1 SAB, 1 preterm, 2 unknown
– Reduced placental transfer
– Not detected in breast milk
• Natalizumab (C):
– IgG4, placental transfer in third trimester
– 143 pregnant patients exposed to tysabri
– No birth defects reported
Mahadevan ACG 2008
20
FDA Database: Anti-TNF’s
• 61 reported CA’s/ 41 offspring (12/2005): – 22 etanercept, 19 INF
– 15 (37%) > 1 CA
– Most common is cardiac defect
– 1 VACTERL (ETN) Separate VACTERL in ADA• 24/41 (59%) had some component of VACTERL (11
INF)
• 24/41 cases (59%) mother on no other meds
• Vertebral, anal atresia, cardiac defect (VSD), tracheosphageal fistula with esoph atresia, renal, limb abnormality (radial dysplasia)
– Associated with DM: Inhibition of cholesterol-dependent sonic-hedgehog morphogenetic pathway
Carter J J Rheumaol 2009;36:3
21
Malignancies
• Three malignancies have been reported in
infants exposed to anti-TNF in utero
– 3 wks/M: sacrococcygeal teratoma
• 3 infusions to mother. On AZA, pred
– 2 mo/F: neuroblastoma of liver, kidneys,
stomach
• 1 infusion 1 month prior to conception
– 4 years: leukemia.
• Unknown dose and duration of therapy. AZA
Centocor Data on File
22
Infliximab in Cord Blood
Pt #
* Breastfed 1 2 3* 4* 5* 6 7* 8* 9 10
Last Dose
(days)30 3 14 90 120 55 46 35 70 74
Mother INF
(mcg/ml)15.1 1.4 19.2 3.8 4.8 14.5 16.5 2.2 4.1 5.1
Cord Blood -- 2.0 26.5 3.3 8.8 20.5 26.5 8.4 13.6 20.4
Newborn 25.3 2.9W:2*
23.6 4.2 8.7 28.2 27.5 10.6 4.72m*
8.41m*
INF undetected
6 2 7 2 3 5 5 4 >3 4
23
Certolizumab Placental Transfer
Interval:
Last dose to
delivery
(weeks)
Maternal
Level DOB
(μg/ml)
Cord Blood
Level DOB
(μg/ml)
Newborn
level DOB
(μg/ml)
Pt 1 2 18.83 1.65 --
Pt 2 < 1 59.57 0.94 1.02
Pt 3 4 4.87 1.19 1.22
Pt 4 2 20.13 0.57 0.44
LOQ 0.41 μg/ml
Mahadevan U Gastroenterology. 2009:Abstract 960.
24
Response to Vaccines
Mean
LevelsRange
(Normal
Range)
# Response
Inadequate
IgG (mg/dl) 416 297-510 (217-904) 0
IgA (mg/dl) 26 12-46 (11-90) 0
IgM (mg/dl) 46 17-129 (34-126) 4/7*
HiB (mcg/ml) 1.09 0.36-9 ( > 1.0 ) 1/9*
Tetanus
Toxoid (IU/ml)4.91 0.33-3.2 ( > 0.15 ) 0
*Only 7/9 patients had Ig levels assessed
25
Timing of Biologics
• Our practice
– Discontinue infliximab at week 30
gestation
– Discontinue adalimumab at week 30-34
– Continue certolizumab throughout
pregnancy
– If mom flares, treat her!
• Breast feeding compatible
• No live virus vaccine to infant if INF/ADA in
utero
26
PIANO:
• Patients classified by exposure to four groups of drugs taken b/w conception and delivery:– Unexposed: no immunomodulators/biologics
• (mesalamine, steroids, antibiotics allowed)
– Group A: AZA/6MP• +/- Unexposed medications
– Group B: INF, ADA, CZP• +/- Unexposed medications
– Group AB: Combination therapy• +/- Unexposed medications
Mahadevan DDW 2010
Pregnancy in Inflammatory
Bowel Disease And Neonatal Outcomes
27
Results
• 605 women enrolled (4/1/2010)
• 417 pregnancies ended (+2 missing outcomes)– Unexposed: n = 166
– Group A: n = 102
– Group B: n = 108• 96 INF
• 59 ADA
• 13 CZP
• 3 Natalizumab
– Group AB: n = 42
27
28
Results (cont)
• Medication use not associated with
increased risk of:
– Any Complication
– Preterm Birth
– Low Birth Weight
– Cesarean section
– Congenital Anomalies
• 17 anomalies/15 births
• Biologic exp: increased risk of NICU stay
• Combination exp: increased risk of
infection at 1 year of age28
29
Summary
• Compatible with use in pregnancy– 5 asa
– Corticosteroids (1st T risk of cleft palate)
– Antibiotics (mnzl after T1)
– Azathioprine/6mp
– Infliximab (discontinue week 30)
– Adalimumab (discontinue week 30-34)
– Certolizumab (continue throughout)
• All of the above compatible with use in lactation– Except metronidazole
– Dose azathioprine/6MP 4 hours prior to feeding
• Recommendations:– Control disease prior to conception
– Continue most medications
– Multidisciplinary approach: High Risk Obstetrician, pediatrician, surgeon if needed